The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Plaquenil: From Malaria Treatment to Managing Lupus, RA

Plaquenil: From Malaria Treatment to Managing Lupus, RA

May 15, 2015 • By Charles Radis, DO

  • Tweet
  • Email
Print-Friendly Version / Save PDF

That left Plaquenil. In the treatment of SLE, it’s widely regarded as a cornerstone drug in the management of skin and arthritis symptoms.

You Might Also Like
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Immunosuppressive Treatment for Lupus in the Next Decade
Explore This Issue
May 2015
Also By This Author
  • Diffuse Scleroderma: A 1991 Case Through the Lens of Today

In RA, Plaquenil is prescribed as monotherapy in mild disease or combined with other disease-modifying medications to control more aggressive disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Plaquenil is included in the World Health Organization’s List of Essential Medicines, a listing of the essential medications needed in a basic health system.8 The drug, in its generic form, is cheap and generally well tolerated. It does not require regular laboratory monitoring. It can be continued in patients receiving antibiotics for bacterial infections. Although it is considered to be a category C drug, it is generally regarded as safe for women to continue on during pregnancy, and lactating women may breastfeed while taking the drug.9

The Research Says …

Like the Cinchona tree, Plaquenil has a number of additional valuable and surprising properties.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The beneficial effects of Plaquenil on lipid profiles have been confirmed in numerous trials.10-12 These effects are relatively small, with decreased LDL and triglycerides, but in RA and SLE, any medication that can partially mitigate the unfavorable lipid profiles of patients often on corticosteroids is not insignificant.

In 1990, the Annals of Internal Medicine published an intriguing article by Antonio Quatraro, MD, “Hydroxy­chloroquine in Decompensated, Treatment-Refractory Non­insulin-Dependent Diabetes Mellitus: A New Job for an Old Drug?”13 This small, prospective, randomized, placebo-controlled trial found clinically meaningful improvement in glucose control with Plaquenil.

Other studies followed. Mary Chester M. Wasko, MD, at the University of Pittsburgh, determined in a large prospective trial of 4,905 adult RA patients that long-term use of Plaquenil reduced the risk of diabetes mellitus.14 Risk reduction was both dose and duration dependent; RA patients taking 400 mg Plaquenil daily for more than than four years had a 77% lower risk of developing diabetes than RA patients who never received the drug.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Lastly, Rekedal and colleagues found significant reductions in glycosylated hemoglobin in established diabetic patients with rheumatic disease after initiation of Plaquenil compared with methotrexate.15 The mean change in HbA1c of 0.66 from baseline was only slightly less than with frequently prescribed oral hypoglycemics.15

For patients at risk of thrombosis, Plaquenil may lower this risk. Michelle Petri, MD, found that in her cohort of 2,000 SLE patients at Johns Hopkins, those with phospholipid/lupus anticoagulants on long-term Plaquenil had a lower risk of thrombosis than those who never took the drug.16 Studies in the early 1970s explored the antithrombotic effects of Plaquenil in patients undergoing hip arthroplasty.17 Although most studies demonstrated moderate efficacy in preventing postoperative deep venous thrombosis, newer regimens with heparin and warfarin have proved superior.

Additional Potential Uses

A number of additional disorders exist for which a trial of Plaquenil is more than reasonable. Dermatologists use the drug for polymorphous light eruptions, granuloma annulare, porphyria cutanea tarda and necrobiosis lipoidica diabeticorum. Rheumatologists are often pleasantly surprised at follow-up that their patient’s undifferentiated connective tissue disorder (UCTD), palindromic rheumatism or inflammatory osteoarthritis has improved. A subset of hypocomplementemic urticarial vasculitis may respond to Plaquenil. Current EULAR recommendations suggest that Plaquenil be considered as an adjunctive treatment in chronic (but not acute) calcium pyrophosphate deposition (CPPD) arthropathy.18

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis, SLE (Lupus) Tagged With: anti-malarial, drug, Lupus, Plaquenil, Rheumatoid arthritisIssue: May 2015

You Might Also Like:
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Immunosuppressive Treatment for Lupus in the Next Decade
  • Updates on Managing Lupus Complications

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.